| 1 | about approach pipeline beyond | | | | | | | 1 | 0.33% |
| 2 | leaders to explore how | | | | | | | 1 | 0.33% |
| 3 | value targets we are | | | | | | | 1 | 0.33% |
| 4 | targets we are collaborating | | | | | | | 1 | 0.33% |
| 5 | we are collaborating with | | | | | | | 1 | 0.33% |
| 6 | are collaborating with a | | | | | | | 1 | 0.33% |
| 7 | collaborating with a wide | | | | | | | 1 | 0.33% |
| 8 | with a wide range | | | | | | | 1 | 0.33% |
| 9 | wide range of pharma | | | | | | | 1 | 0.33% |
| 10 | partners and leading academic | | | | | | | 1 | 0.33% |
| 11 | and leading academic thought | | | | | | | 1 | 0.33% |
| 12 | leading academic thought leaders | | | | | | | 1 | 0.33% |
| 13 | academic thought leaders to | | | | | | | 1 | 0.33% |
| 14 | thought leaders to explore | | | | | | | 1 | 0.33% |
| 15 | to explore how we | | | | | | | 1 | 0.33% |
| 16 | of hardtotarget but potentially | | | | | | | 1 | 0.33% |
| 17 | explore how we might | | | | | | | 1 | 0.33% |
| 18 | effectively apply our unique | | | | | | | 1 | 0.33% |
| 19 | apply our unique technology | | | | | | | 1 | 0.33% |
| 20 | our unique technology to | | | | | | | 1 | 0.33% |
| 21 | unique technology to develop | | | | | | | 1 | 0.33% |
| 22 | technology to develop innovative | | | | | | | 1 | 0.33% |
| 23 | medicines in a range | | | | | | | 1 | 0.33% |
| 24 | in a range of | | | | | | | 1 | 0.33% |
| 25 | a range of therapeutic | | | | | | | 1 | 0.33% |
| 26 | range of therapeutic areas | | | | | | | 1 | 0.33% |
| 27 | of therapeutic areas antiinfective | | | | | | | 1 | 0.33% |
| 28 | therapeutic areas antiinfective cardiovascular | | | | | | | 1 | 0.33% |
| 29 | ophthalmology dementia central nervous | | | | | | | 1 | 0.33% |
| 30 | hardtotarget but potentially high | | | | | | | 1 | 0.33% |
| 31 | variety of hardtotarget but | | | | | | | 1 | 0.33% |
| 32 | central nervous system neuromuscular | | | | | | | 1 | 0.33% |
| 33 | beyond oncology where there | | | | | | | 1 | 0.33% |
| 34 | and have been developed | | | | | | | 1 | 0.33% |
| 35 | have been developed primarily | | | | | | | 1 | 0.33% |
| 36 | been developed primarily to | | | | | | | 1 | 0.33% |
| 37 | target solid tumor cancers | | | | | | | 1 | 0.33% |
| 38 | solid tumor cancers however | | | | | | | 1 | 0.33% |
| 39 | tumor cancers however we | | | | | | | 1 | 0.33% |
| 40 | cancers however we are | | | | | | | 1 | 0.33% |